PT90195A - Processo para a preparacao de hetero conjugados de anticorpos para utilizacao na regulacao da actividade linfocitica - Google Patents

Processo para a preparacao de hetero conjugados de anticorpos para utilizacao na regulacao da actividade linfocitica

Info

Publication number
PT90195A
PT90195A PT90195A PT9019589A PT90195A PT 90195 A PT90195 A PT 90195A PT 90195 A PT90195 A PT 90195A PT 9019589 A PT9019589 A PT 9019589A PT 90195 A PT90195 A PT 90195A
Authority
PT
Portugal
Prior art keywords
heteroconjugates
antibodies
regulation
lymphocytes
conjugates
Prior art date
Application number
PT90195A
Other languages
English (en)
Other versions
PT90195B (pt
Inventor
Jeffrey A Ladbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of PT90195A publication Critical patent/PT90195A/pt
Publication of PT90195B publication Critical patent/PT90195B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT90195A 1988-04-04 1989-04-04 Processo para a preparacao de hetero conjugados de anticorpos para utilizacao na regulacao da actividade linfocitica PT90195B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US27193488A 1988-11-14 1988-11-14

Publications (2)

Publication Number Publication Date
PT90195A true PT90195A (pt) 1989-11-10
PT90195B PT90195B (pt) 1994-06-30

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
PT90195A PT90195B (pt) 1988-04-04 1989-04-04 Processo para a preparacao de hetero conjugados de anticorpos para utilizacao na regulacao da actividade linfocitica

Country Status (20)

Country Link
EP (1) EP0336379B1 (pt)
JP (1) JP2613106B2 (pt)
KR (1) KR100205833B1 (pt)
CN (1) CN1058296C (pt)
AT (1) ATE133866T1 (pt)
AU (1) AU629204B2 (pt)
DE (1) DE68925593T2 (pt)
DK (1) DK173382B1 (pt)
ES (1) ES2083960T3 (pt)
FI (1) FI105320B (pt)
GR (1) GR3019224T3 (pt)
HU (1) HU213576B (pt)
IE (1) IE72187B1 (pt)
IL (1) IL89823A (pt)
MY (1) MY106592A (pt)
NO (1) NO178699C (pt)
NZ (1) NZ228560A (pt)
PT (1) PT90195B (pt)
YU (1) YU68589A (pt)
ZA (1) ZA892448B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
CA2071478A1 (en) * 1989-10-27 1991-04-28 Jeffery A. Bluestone Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0564735B1 (en) * 1992-04-10 1998-11-18 Thomas Totterman Method for detection of CMV infection
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
DK0758394T3 (da) 1994-05-02 2003-03-03 Bernd Groner Bifunktionelt protein, fremstilling og anvendelse
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (en) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Methods and means for the treatment of immune related diseases such as Graft vs. Host disease
WO2000078348A1 (en) * 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
WO2021160267A1 (en) * 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (en) * 1984-03-01 1987-07-01 Centocor, Inc. Antibody enhancement of immunogenicity of antigen
WO1985004811A1 (en) * 1984-04-23 1985-11-07 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
ATE108068T1 (de) * 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.

Also Published As

Publication number Publication date
NO891375L (no) 1989-10-05
EP0336379A2 (en) 1989-10-11
IE891054L (en) 1989-10-04
AU629204B2 (en) 1992-10-01
PT90195B (pt) 1994-06-30
NO178699C (no) 1996-05-15
ZA892448B (en) 1989-12-27
EP0336379B1 (en) 1996-02-07
CN1058296C (zh) 2000-11-08
ATE133866T1 (de) 1996-02-15
IE72187B1 (en) 1997-03-26
HUT51338A (en) 1990-04-28
DE68925593T2 (de) 1996-06-13
DK173382B1 (da) 2000-09-11
FI891528A (fi) 1989-10-05
KR100205833B1 (ko) 1999-07-01
FI891528A0 (fi) 1989-03-30
NZ228560A (en) 1991-10-25
KR890015751A (ko) 1989-11-25
IL89823A (en) 1994-07-31
DK159489A (da) 1989-10-05
AU3242389A (en) 1989-10-05
YU68589A (en) 1991-10-31
EP0336379A3 (en) 1990-01-31
GR3019224T3 (en) 1996-06-30
FI105320B (fi) 2000-07-31
CN1036988A (zh) 1989-11-08
NO178699B (no) 1996-02-05
JPH01304356A (ja) 1989-12-07
MY106592A (en) 1995-06-30
IL89823A0 (en) 1989-12-15
DK159489D0 (da) 1989-04-03
NO891375D0 (no) 1989-03-31
ES2083960T3 (es) 1996-05-01
DE68925593D1 (de) 1996-03-21
HU213576B (en) 1997-08-28
JP2613106B2 (ja) 1997-05-21

Similar Documents

Publication Publication Date Title
PT90195A (pt) Processo para a preparacao de hetero conjugados de anticorpos para utilizacao na regulacao da actividade linfocitica
ATE47155T1 (de) Monoklonaler antikoerper.
ATE137802T1 (de) Monoklonaler antikörper, der mit einer neuen hla- determinante auf mhc-klasse-i-moleküle reagiert, und verfahren zur aktivierung von lymphozyten
DE3879000D1 (de) Immunoassaymethode zum auffinden von antikoerpern zu antigenen.
ES2091202T3 (es) Composicion y metodos para determinar la presencia de anfetaminas en una muestra de la que se sospecha que contiene anfetamina y/o metanfetamina.
FI874047A (fi) Monoklonaalisia vasta-ainemolekyylejä, joilla on katalyyttisiä ominaisuuksia omaavia vasta-aineen sitovia kohtia
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
ES2116789T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
EP0363109A3 (en) Determination of a chlamydial or gonococcal antigen using a positively-charged ionically binding support
ATE88901T1 (de) Fluorkohlenstoffkette enthaltende antigene konjugate.
ATE90790T1 (de) Verfahren zur herstellung einer festphasenmatrix.
NO168746C (no) Antistoff som er istand til aa binde histamin
ATE132267T1 (de) Immuntest unter verwendung von antigenen, produziert in heterologen organismen
ATE110469T1 (de) Nichttrennender festphasen-enzymtest.
ATE27494T1 (de) Diagnostisches testsystem.
ES551762A0 (es) Procedimiento para la determinacion de la capacidad de fijacion de la globulina fijadora de tiroxina
PT81050B (pt) Anticorpo monoclonal anti-urocinase e processo para a preparacao de composicoes de materia de teste biologicos que o utilizam
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DK673789A (da) Monoklonalt antistof, som specifikt binder til kc-48-antigenet i neutrophiler og eosinophiler, samt hybridomocellelinie, som producerer antistoffet

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19931206

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20090404